

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 03/078639 A2

- (51) International Patent Classification⁷: **C12N 15/82** (74) Agent: **HARRISON GODDARD FOOTE**; 31 St. Saviourgate, York YO1 8NQ (GB).
- (21) International Application Number: **PCT/GB03/01099**
- (22) International Filing Date: **17 March 2003 (17.03.2003)**
- (25) Filing Language: **English**
- (26) Publication Language: **English**
- (30) Priority Data:
- | | | |
|-----------|------------------------------|----|
| 0206308.9 | 16 March 2002 (16.03.2002) | GB |
| 0212133.3 | 25 May 2002 (25.05.2002) | GB |
| 0216013.3 | 11 July 2002 (11.07.2002) | GB |
| 0225489.4 | 1 November 2002 (01.11.2002) | GB |
- (71) Applicant (for all designated States except US): **THE UNIVERSITY OF YORK [GB/GB];** Heslington, York YO1 5DD (GB).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): **GRAHAM, Ian, Alexander [GB/GB];** Department of Biology, The University of York, P.O. Box 373, York YO10 5YW (GB). **TONON, Thierry [FR/GB];** Department of Biology, The University of York, P.O. Box 373, York YO10 5YW (GB).
- (81) Designated States (national): **AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.**
- (84) Designated States (regional): **ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).**
- Published:**
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 03/078639 A2

(54) Title: **TRANSGENIC PLANTS EXPRESSING ENZYMES INVOLVED IN FATTY ACID BIOSYNTHESIS**

(57) Abstract: The invention relates to nucleic acid molecules which comprise nucleic acid sequences which encode enzymes involved in the biosynthesis of n-3 fatty acids, particularly docosahexanoic acid (DHA), or variants thereof; polypeptides encoded by said nucleic acids; cells transfected with said nucleic acid sequences and products comprising said nucleic acid sequences, polypeptides and/or cells.

Transgenic Plants Expressing Enzymes Involved in Fatty Acid Biosynthesis

The invention relates to nucleic acid molecules which comprise nucleic acid sequences which encode enzymes involved in the biosynthesis of n-3 fatty acids, particularly docosahexanoic acid, or variants thereof; polypeptides encoded by said nucleic acids; cells transfected with said nucleic acid sequences and products comprising said nucleic acid sequences, polypeptides and/or cells.

DHA, an example of a n-3 fatty acid can be obtained directly from the diet or derived from metabolism of dietary linoleic and α -linolenic acid. To obtain sufficient amounts of this fatty acid humans have to eat foods rich in DHA. Currently the principle dietary source of DHA is fish or fish oil. However, this has many inherent problems; fish accumulate pollutants, the extracted oil has an unpleasant odour, there is a difficulty in controlling the proportion of specific desirable fatty acids from this source and since fish are a declining resource the market demand for DHA is not being met. Also, vegetarians do not have an obvious alternative food source to fish and therefore either do without DHA or have to take pure supplements.

Long chain polyunsaturated fatty acids (LPUFAs) are derived from the essential fatty acids (EFA) linoleic acid (18:2n-6) and α -linolenic acid (18:3n-3), the parent compounds of the so-called omega-3 and omega-6 EFA families by an alternating series of desaturation and elongation reactions (Haag, 2001), see Figure 4. The major metabolite product of the n-6 pathway in mammals is arachidonic acid (AA) (20:4n-6), whilst the major end products of the n-3 pathway are eicosapentaenoic acid (EPA) (20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3). The biosynthesis of 18:3n-3 from 18:4n-3 involves the action of a Δ 6 desaturase (Horrobin DF, 1992). This is followed by an elongation reaction to 20:4n-3 (Sprecher *et al.*, 1995) and a Δ 5 desaturation to 20:5n-3 (Sprecher *et al.*, 1995). The conventional view is that there is then a further elongation step converting 20:5n-3 to 22:5n-3, which is then followed

by a final desaturation step involving the activity of a $\Delta 4$ desaturase to produce DHA (22:6n-3).

During evolution humans have consumed a diet containing approximately equal ratio of n-3 and n-6 essential fatty acids (1-2:1), but the last 100-150 years has seen a growing trend in Western diets towards the consumption of more n-6 fatty acids, resulting in an alteration of the ratio to 30:1 (Simonpolous, 1999). Whilst an increased intake of n-6 fatty acids is characterised by cardiovascular problems such as increased blood viscosity, vasospasm and vasoconstriction, the n-3 fatty acids are associated with health promoting properties. For example n-3 fatty acids have been described as anti-inflammatory, antithrombotic, antiarrhythmic, hypolipidemic and vasodilatory (Simonpolous, 1999). As such the role of DHA in the prevention and/or treatment of diseases such as coronary heart disease, hypertension, type II diabetes, ocular diseases, arthritis, cystic fibrosis and schizophrenia and has been the focus of a great deal of medical research.

The effect of n-3 polyunsaturated fatty acids in the cardiovascular diseases has shown that dietary intake of DHA can lower the risk of myocardial infarction, hypertension and complications associated with cardiac surgery. A number of population studies have correlated the dietary intake of DHA with cardiovascular risk factors. For instance, a study of a population of Inuits in Canada (426 subjects aged 18-74 yr), who traditionally consume large amounts of marine foods rich in n-3 fatty acids, showed that n-3 fatty acids, such as DHA were positively associated with HDL-cholesterol concentrations and inversely associated with triacylglycerol concentrations and the ratio of total to HDL cholesterol (Dewailly *et al.*, 2001). It was concluded that the high dietary intake of n-3 fatty acids in the Inuit diet was probably responsible for the low mortality rate from ischemic heart disease in this population.

Essential fatty acids are structural components of all tissues and are indispensable for cell membrane synthesis. The brain, retina and other neural tissues have been found to be particularly rich in DHA, where it is involved in neural development and

maturation of sensory systems (Uauy *et al.*, 2000). A large body of research comparing infants fed with breast milk compared to formula milk, which is deficient in DHA and other omega 3- fatty acids, has concluded that the presence of DHA is critical during the development of the newborn (Horrocks *et al.*, 1999). DHA forms 25% of the fatty acid complement of the glycosphingolipids of the brain and is an important component of the rods of the retina, and therefore a deficiency in DHA during infant development has been associated with a reduction in cognitive function and visual acuity. Furthermore, deficiencies in DHA have been associated with foetal alcohol syndrome, attention deficit hyperactivity disorder, cystic fibrosis, phenylketonuria and adrenoleukodystrophy.

To meet this increased demand for n-3 fatty acids such as DHA a number of approaches have been attempted. Methods to enhance the DHA content of meat by manipulating animal feed have been met with little success. The cultivation of marine micro-organisms such as the *Cryptocodinium cohnii* and *Schizochytrium* sp, which are rich sources of DHA has also met with some limited success as the cultivation of algae is technically demanding and costly (Ashford *et al.*, 2000).

There has been limited research focused on the identification of genes involved in the biosynthesis of n-3 fatty acids in algae. In one report the identification of a cDNA encoding a novel C18- Δ^9 polyunsaturated fatty acid-specific elongating activity from the docosahexaenoic acid (DHA)-producing microalga, *Isochrysis galbana* was described (Qi *et al.*, 2002). This 30 kDa elongase, designated IgASE1, shares only limited homology to animal and fungal proteins with elongating activity. When IgASE1 was expressed in the yeast *Saccharomyces cerevisiae*, it was shown to specifically elongate the C18- Δ^9 polyunsaturated fatty acids, linoleic acid (C18:2n-6, $\Delta^{9,12}$ and alpha-linolenic acid (C18:3, $\Delta^{9,12,15}$), to eicosadienoic acid (C20:2, $\Delta^{11,14}$) and eicosatrienoic acid (C20:3 $\Delta^{11,14,17}$), respectively. It was concluded that a major route for eicosapentaenoic acid (C20:5 $\Delta^{5,8,11,14,17}$) and docosahexaenoic acid (C22:6 $\Delta^{4,7,10,13,16,19}$) syntheses in *I. galbana* may involve a Δ^8 desaturation pathway.

$\Delta 6$ and $\Delta 5$ desaturases are microsomal enzymes that are thought to be a component of a three-enzyme system that includes NADH-cytochrome b_5 reductase, cytochrome b_5 , and the respective desaturase (Sprecher, 1981).

5

A number of $\Delta 6$ and $\Delta 5$ desaturases have been identified. In plants such as the herb, borage (*Borago officinalis*), the $\Delta 6$ desaturase has been identified (Sayanova *et al.*, 1997). $\Delta 6$ and $\Delta 5$ desaturases have been identified in humans (Hyekyung *et al.*, 1999 and Cho *et al.*, 1999, respectively), in animals such as the nematode; *Caenorhabditis*
10 *elegans* (Michaelson *et al.*, 1998 and Napier *et al.*, 1998) and in eukaryotic microorganisms such as the fungus *Mortierella alpina* (Huang *et al.*, 1999 and Knutzon *et al.*, 1998). In the human, $\Delta 6$ and $\Delta 5$ desaturase activities have been found in skeletal muscle, lung, placenta, kidney and pancreas, but are expressed at the highest levels in the liver, brain and heart (Hyekyung *et al.*, 1999). In all these tissues
15 however, $\Delta 6$ desaturase activity was found to be higher than that of $\Delta 5$ desaturase. The genes for both of the enzymes reside on chromosome 11, in a reverse orientation, being separated by <11,000 base pairs (Hyekyung *et al.*, 1999). A $\Delta 4$ desaturase that can introduce a double bond at position 4 of 22:5 n-3 and 22:4 n-6 resulting in the production of DHA and docosapentanoic acid has been identified in the marine fungi
20 *Thraustochytrium* sp (Qiu *et al.*, 2001).

Cellular storage of fatty acids in triacylglycerol requires that the fatty acids are first activated to their acyl-CoA esters through the action of acyl-CoA synthetase enzyme. Acyl-CoA's are produced by acyl-CoA synthetase from fatty acid, ATP and
25 Coenzyme A. Acyl-CoA synthetases can exhibit substrate specificity for different chain length or different degrees of saturation of the fatty acid. For example an arachidonate (20:4 n-6)-preferring acyl-CoA synthetase has been identified in rat (Kang *et al.*, 1997). This enzyme has a high affinity for arachidonate and EPA and low affinity for palmitate. Several isoforms of acyl-CoA synthetases have also been
30 identified in *Arabidopsis* (Schnurr *et al.*, 2000).

Acyl CoA:diacylglycerol acyltransferase (DGAT) catalyses the final enzymatic step in the production of triacylglycerols in plants, fungi and mammals. The enzyme is responsible for transferring an acyl group from acyl-CoA to the *sn*-3 position of 1,2-diacylglycerol (DAG) to form triacylglycerol (TAG). The first cloning of a DGAT gene was from mouse (Cases *et al.*, 1998). An *Arabidopsis* homologue of the mouse DGAT gene was subsequently reported and found to be present as a single copy gene (Hobbs *et al.*, 1999). Jako *et al.*, (2001) showed that the *Arabidopsis Tag1* mutant which is disrupted in the DGAT gene and has a fatty acid and reduced oil phenotype can be complemented by expression of the DGAT cDNA. Jako *et al.*, (2001) also showed that seed-specific over-expression of the DGAT cDNA in wild-type *Arabidopsis* enhances oil deposition and average seed weight thus confirming the important role of DGAT in regulating the quantity of seed triacylglycerols and the sink size in developing seeds. Protein purification based studies on the oleaginous fungus *Mortierella ramanniana* resulted in the identification of a second class of proteins involved in TAG production that are encoded by the *DGAT2* gene family that are unrelated to the previously identified *DGAT1* gene family (Lardizabal *et al.*, 2001). A human homologue of the *Mortierella ramanniana* *DGAT2* gene has been also been identified (Cases *et al.*, 2001). Substrate specificities of the different families have yet to be determined.

Whilst higher plants do not typically biosynthesise LPUFAs such as DHA, they are an attractive target for genetic manipulation, particularly the low cost production of DHA in the vegetable oil of a crop such as oilseed rape. There have been no reports of higher plants that biosynthesise DHA, a number of attempts to introduce algal genes in order to manipulate the biosynthetic capacity of oil seed plants that produce LPUFAs have been reported. These have included the introduction of desaturases into transgenic plants to increase the production of DHA, EPA and also stearidonic acid (18:4n-3).

We herein disclose nucleic acid sequences which encode enzymes involved in n-3 fatty acid metabolism and the manipulation of these sequences and the biochemical pathways which comprise enzymes encoded by these sequences, to provide an alternative dietary source of n-3 fatty acids and, in particular, DHA. The sequences
5 encode n-3 fatty acid elongase, desaturase, acyl CoA synthetase and diacylglycerol acyltransferase activities

According to an aspect of the invention there is provided an isolated nucleic acid molecule comprising a DNA sequence selected from the group consisting of:

- 10 (i) the DNA sequence as represented in Figures 1a, 2a, 3a, 3d, 4a, 6a, 7a, 7c and 8a;
- (ii) DNA sequences which hybridise to the sequence identified in (i) above; and
- (iii) DNA sequences that are degenerate as a result of the genetic code to
15 the DNA sequence defined in (i) and (ii)

In a preferred embodiment of the invention there is provided an isolated nucleic acid molecule which anneals under stringent hybridisation conditions to the sequences described in (i), (ii) and (iii) above.

20 Stringent hybridisation/washing conditions are well known in the art. For example, nucleic acid hybrids that are stable after washing in 0.1xSSC, 0.1% SDS at 60°C. It is well known in the art that optimal hybridisation conditions can be calculated if the sequence of the nucleic acid is known. Typically, hybridisation conditions uses 4 – 6
25 x SSPE (20x SSPE contains 175.3g NaCl, 88.2g NaH₂PO₄ H₂O and 7.4g EDTA dissolved to 1 litre and the pH adjusted to 7.4); 5-10x Denhardt's solution (50x Denhardt's solution contains 5g Ficoll (Type 400, Pharmacia), 5g polyvinylpyrrolidone and 5g bovine serum albumen); 100µg-1.0mg/ml sonicated salmon/herring DNA; 0.1-1.0% sodium dodecyl sulphate; optionally 40-60%
30 deionised formamide. Hybridisation temperature will vary depending on the GC content of the nucleic acid target sequence but will typically be between 42° - 65° C.

In a preferred embodiment of the invention said nucleic acid molecules are isolated from an algal species.

Preferably said algal species is selected from the group consisting of: *Amphidinium carterae*, *Amphiphora hyalina*, *Amphiphora sp.*, *Chaetoceros gracilis*, *Coscinodiscus sp.*, *Crypthecodinium cohnii*, *Cryptomonas sp.*, *Cylindrotheca fusiformis*, *Haslea ostrearia*, *Isochrysis galbana*, *Nannochloropsis oculata*, *Navicula sp.*, *Nitzschia closterium*, *Pavlova lutheri*, *Phaeodactylum tricornutum*, *Prorocentrum minimum*, *Rhizosolenia setigera*, *Skeletonema costatum*, *Skeletonema sp.*, *Tetraselmis tetrathele*, *Thalassiosira nitzschiioides*, *Thalassiosira heterophorma*, *Thalassiosira pseudonana*, *Thalassiosira stellaris*.

According to a further aspect of the invention there is provided a polypeptide encoded by a nucleic acid molecule according to the invention.

In a preferred embodiment of the invention said polypeptide is a variant polypeptide and comprises the amino acid sequence represented in Figure 1b, 2b, 3b, 3c, 4b, 6b, 7b, 7d, or 8b which sequence has been modified by deletion, addition or substitution of at least one amino acid residue wherein said modification enhances the enzyme activity of said polypeptide.

A variant polypeptide may differ in amino acid sequence by one or more substitutions, additions, deletions, truncations which may be present in any combination. Among preferred variants are those that vary from a reference polypeptide by conservative amino acid substitutions. Such substitutions are those that substitute a given amino acid by another amino acid of like characteristics. The following non-limiting list of amino acids are considered conservative replacements (similar): a) alanine, serine, and threonine; b) glutamic acid and aspartic acid; c) asparagine and glutamine d) arginine and lysine; e) isoleucine, leucine, methionine and valine and f) phenylalanine, tyrosine and tryptophan. Most highly preferred are

variants which retain or enhance the same biological function and activity as the reference polypeptide from which it varies.

5 A functionally equivalent polypeptide(s) according to the invention is a variant wherein one in which one or more amino acid residues are substituted with conserved or non-conserved amino acid residues, or one in which one or more amino acid residues includes a substituent group. Conservative substitutions are the replacements, one for another, among the aliphatic amino acids Ala, Val, Leu and Ile; interchange of the hydroxyl residues Ser and Thr; exchange of the acidic residues
10 Asp and Glu; substitution between amide residues Asn and Gln; exchange of the basic residues Lys and Arg; and replacements among aromatic residues Phe and Tyr.

In addition, the invention features polypeptide sequences having at least 75% identity with the polypeptide sequences as herein disclosed, or fragments and functionally equivalent polypeptides thereof. In one embodiment, the polypeptides have at least
15 85% identity, more preferably at least 90% identity, even more preferably at least 95% identity, still more preferably at least 97% identity, and most preferably at least 99% identity with the amino acid sequences illustrated herein.

Ideally said modified polypeptide has enhanced fatty acid elongase, desaturase, acyl-
20 CoA synthetase or diacylglycerol acyltransferase activity.

In a further preferred embodiment of the invention said polypeptide comprises the amino acid sequence represented in Figures 2b, 3b, 3c, 4b, 6b, 7b, 7d, 8b. Preferably said polypeptide consists of the amino acid sequence represented in Figure 2b, 3b, 3c,
25 4b, 6b, 7b, 7d, 8b.

According to a further aspect of the invention there is provided a vector including at least one nucleic acid according to the invention.

A vector including nucleic acid (s) according to the invention need not include a promoter or other regulatory sequence, particularly if the vector is to be used to introduce the nucleic acid into cells for recombination into the genome for stable transfection.

5

Preferably the nucleic acid in the vector is operably linked to an appropriate promoter or other regulatory elements for transcription in a host cell such as a prokaryotic, (e.g. bacterial), or eukaryotic (e.g. fungal, plant, mammalian or insect cell). The vector may be a bi-functional expression vector which functions in multiple hosts. In the example of nucleic acids encoding polypeptides according to the invention this may contain its native promoter or other regulatory elements and in the case of cDNA this may be under the control of an appropriate promoter or other regulatory elements for expression in the host cell.

15 By "promoter" is meant a nucleotide sequence upstream from the transcriptional initiation site and which contains all the regulatory regions required for transcription. Suitable promoters include constitutive, tissue-specific, inducible, developmental or other promoters for expression in plant cells comprised in plants depending on design. Such promoters include viral, fungal, bacterial, animal and plant-derived
20 promoters capable of functioning in plant cells.

Constitutive promoters include, for example CaMV 35S promoter (Odell *et al* (1985) Nature 313, 9810-812); rice actin (McElroy *et al* (1990) Plant Cell 2: 163-171); ubiquitin (Christian *et al* . (1989) Plant Mol. Biol. 18 (675-689); pEMU (Last *et al* 25 (1991) Theor Appl. Genet. 81: 581-588); MAS (Velten *et al* (1984) EMBO J. 3. 2723-2730); ALS promoter (U.S. Application Serial No. 08/409,297), and the like. Other constitutive promoters include those in U.S. Patent Nos. 5,608,149; 5,608,144; 5,604,121; 5,569,597; 5,466,785; 5,399,680, 5,268,463; and 5,608,142.

30 Chemical-regulated promoters can be used to modulate the expression of a gene in a plant through the application of an exogenous chemical regulator. Depending upon

the objective, the promoter may be a chemical-inducible promoter, where application of the chemical induced gene expression, or a chemical-repressible promoter, where application of the chemical represses gene expression. Chemical-inducible promoters are known in the art and include, but are not limited to, the maize In2-2 promoter, which is activated by benzenesulfonamide herbicide safeners, the maize GST promoter, which is activated by hydrophobic electrophilic compounds that are used as pre-emergent herbicides, and the tobacco PR-1a promoter, which is activated by salicylic acid. Other chemical-regulated promoters of interest include steroid-responsive promoters (see, for example, the glucocorticoid-inducible promoter in Schena *et al* (1991) Proc. Natl. Acad. Sci. USA 88: 10421-10425 and McNellie *et al.* (1998) Plant J. 14(2): 247-257) and tetracycline-inducible and tetracycline-repressible promoters (see, for example, Gatz *et al.* (1991) Mol. Gen. Genet. 227: 229-237, and US Patent Nos. 5,814,618 and 5,789,156, herein incorporated by reference.

15

Where enhanced expression in particular tissues is desired, tissue-specific promoters can be utilised. Tissue-specific promoters include those described by Yamamoto *et al.* (1997) Plant J. 12(2): 255-265; Kawamata *et al* (1997) Plant Cell Physiol. 38(7): 792-803; Hansen *et al* (1997) Mol. Gen. Genet. 254(3): 337-343; Russell *et al.* (1997) Transgenic Res. 6(2): 157-168; Rinehart *et al* (1996) Plant Physiol. 112(3): 1331-1341; Van Camp *et al* (1996) Plant Physiol. 112(2): 525-535; Canevascni *et al* (1996) Plant Physiol. 112(2): 513-524; Yamamoto *et al* (1994) Plant Cell Physiol. 35(5): 773-778; Lam (1994) Results Probl. Cell Differ. 20: 181-196; Orozco *et al* (1993) Plant Mol. Biol. 23(6): 1129-1138; Mutsuoka *et al* (1993) Proc. Natl. Acad. Sci. USA 90(20): 9586-9590; and Guevara-Garcia *et al* (1993) Plant J. 4(3): 495-50.

25

In a preferred embodiment of the invention said tissue specific promoter is a promoter which is active during the accumulation of oil in developing oil seeds, see Broun *et al.* (1998) Plant J. 13(2): 201-210.

30

"Operably linked" means joined as part of the same nucleic acid molecule, suitably positioned and oriented for transcription to be initiated from the promoter. DNA operably linked to a promoter is "under transcriptional initiation regulation" of the promoter.

5

In a preferred embodiment the promoter is an inducible promoter or a developmentally regulated promoter.

Particular vectors are nucleic acid constructs which operate as plant vectors. Specific procedures and vectors previously used with wide success upon plants are described by Guerineau and Mullineaux (1993) (Plant transformation and expression vectors. In: Plant Molecular Biology Labfax (Croy RRD ed) Oxford, BIOS Scientific Publishers, pp 121-148. Suitable vectors may include plant viral-derived vectors (see e.g. EP-A-194809).

15

Vectors may also include selectable genetic marker such as those that confer selectable phenotypes such as resistance to herbicides (e.g. kanamycin, hygromycin, phosphinotricin, chlorsulfuron, methotrexate, gentamycin, spectinomycin, imidazolinones and glyphosate).

20

Alternatively, or in addition, said vectors are vectors suitable for mammalian cell transfection or yeast cell transfection. In the latter example multi-copy vectors such as 2 μ episomal vectors are preferred. Alternatively yeast CEN vectors and integrating vectors such as YIP vectors are suitable for transformation of yeast species such as *Saccharomyces cerevisiae* and *Pichia* spp.

25

It will be apparent to one skilled in the art that a vector according to the invention may include nucleic acid molecules encoding different enzyme activities to facilitate the delivery of different enzyme activities to a transfected or transformed cell to reconstitute enzymic pathways.

30

According to a further aspect of the invention there is provided a cell transfected or transformed with at least one nucleic acid molecule or vector according to the invention.

- 5 Preferably said cell is transformed or transfected with at least two nucleic acid molecules according to the invention. Preferably still said cell is transformed with at least three nucleic acid molecules according to the invention, more preferably still, four nucleic acid molecules.
- 10 In a further preferred embodiment of the invention said cell is transformed with nucleic acid molecules encoding elongase, desaturase, acyl-CoA synthetase and diacylglycerol acyltransferase activities to provide a cell in which at least part of a 3-n fatty acid biosynthetic pathway is reconstituted.
- 15 In a yet further preferred embodiment of the invention said nucleic acid molecules are those molecules disclosed herein. In particular nucleic acid molecules which comprise the sequences as represented by Figures 1a, 2a, 3a, 3d, 4a, 6a, 7a, 7c and 8a and including a nucleic acid molecule which encodes a desaturase as represented by the amino acid sequence presented in Figure 5, Tsp FAD4.

20

In a preferred embodiment of the invention said cell is selected from the group consisting of: mammalian cells (e.g Chinese Hamster Ovary cells); yeast cells (e.g. *Saccharomyces spp*, *Pichia spp*); algal cells (e.g *Phaeodactylum tricornutum*, *Chlamydomonas reinhardtii*); plant cells.

25

In a preferred embodiment of the invention said cell is a plant cell.

According to a further aspect of the invention there is provided a plant comprising a cell according to the invention.

30

In a preferred embodiment of the invention said plant is selected from: corn (*Zea mays*), canola (*Brassica napus*, *Brassica rapa ssp.*), flax (*Linum usitatissimum*),

alfalfa (*Medicago sativa*), rice (*Oryza sativa*), rye (*Secale cereale*), sorghum (*Sorghum*
bicolor, *Sorghum vulgare*), sunflower (*Helianthus annuus*), wheat (*Triticum aestivum*),
 soybean (*Glycine max*), tobacco (*Nicotiana tabacum*), potato (*Solanum tuberosum*),
 peanuts (*Arachis hypogaea*), cotton (*Gossypium hirsutum*), sweet potato (*Iopmoea*
 5 *batatus*), cassava (*Manihot esculenta*), coffee (*Cofea spp.*), coconut (*Cocos nucifera*),
 pineapple (*Anana comosus*), citris tree (*Citrus spp.*) cocoa (*Theobroma cacao*), tea
 (*Camellia senensis*), banana (*Musa spp.*), avacado (*Persea americana*), fig (*Ficus*
casica), guava (*Psidium guajava*), mango (*Mangifer indica*), olive (*Olea europaea*),
 papaya (*Carica papaya*), cashew (*Anacardium occidentale*), macadamia (*Macadamia*
 10 *intergrifolia*), almond (*Prunus amygdalus*), sugar beets (*Beta vulgaris*), oats, barley,
 vegetables and ornamentals.

Preferably, plants of the present invention are crop plants (for example, cereals and
 pulses, maize, wheat, potatoes, tapioca, rice, sorghum, millet, cassava, barley, pea),
 15 and other root, tuber or seed crops. Important seed crops are oil-seed rape, sugar
 beet, maize, sunflower, soybean, sorghum, and flax (linseed). Horticultural plants to
 which the present invention may be applied may include lettuce, endive, and
 vegetable brassicas including cabbage, broccoli, and cauliflower. The present
 invention may be applied in tobacco, cucurbits, carrot, strawberry, sunflower, tomato,
 20 pepper.

Grain plants that provide seeds of interest include oil-seed plants and leguminous
 plants. Seeds of interest include grain seeds, such as corn, wheat, barley, rice,
 sorghum, rye, etc. Oil-seed plants include cotton, soybean, safflower, sunflower,
 25 Brassica, maize, alfalfa, palm, coconut, etc. Leguminous plants include beans and
 peas. Beans include guar, locust bean, fenugreek, soybean, garden beans, cowpea,
 mungbean, lima bean, fava been, lentils, chickpea, etc.

It will be apparent that transgenic plants adapted for the production of n-3 fatty
 30 acids, in particular DHA, can either be eaten directly or used as a source for the
 extraction of essential fatty acid, of which DHA would be a constituent.

According to a yet further aspect of the invention there is provided a seed comprising a cell according to the invention.

- 5 In a further preferred embodiment of the invention said cell is a yeast cell, preferably of the genus *Saccharomyces spp*, preferably Brewer's yeast *Saccharomyces cerevisiae*.

- The genus *Saccharomyces spp* is used in both brewing of beer and wine making and
10 also as an agent in baking, particularly bread. Yeast is a major constituent of vegetable extracts of which Marmitetm is a typical example. Yeast is also used as an additive in animal feed. It will be apparent that genetically engineered yeast strains can be provided which are adapted to synthesise n-3 fatty acids. These yeast strains can then be used in food stuffs and in wine and beer making to provide products
15 which have enhanced n-3 fatty acid content and in particular DHA content.

According to a further aspect of the invention there is provided a foodstuff product comprising a yeast cell according to the invention.

- 20 In a preferred embodiment of the invention said foodstuff product is selected from the group consisting of: wine; beer; bread, baking products (e.g. bread, cake); vegetable extracts.

- In a further preferred embodiment of the invention said wine or beer is non-
25 alcoholic.

According to a further aspect of the invention there is provided a fermentation process comprising a yeast cell according to the invention.

- 30 In a preferred embodiment of the invention said fermentation process comprises the steps of:

- i) providing a vessel containing a yeast cell according to the invention and constituents required for fermentation and fatty acid biosynthesis; and
- ii) providing conditions conducive to the fermentation of the liquid composition contained in said vessel.
- 5

According to a yet further aspect of the invention there is provided an animal feed product comprising a cell according to the invention.

- 10 In a preferred embodiment of the invention said cell is a plant cell or yeast cell.

According to a further aspect of the invention there is provided a method of modulating the level of n-3 fatty acid, in particular DHA, or variants thereof, in a plant cell comprising;

15

- i) providing a plant cell according to the invention;
- ii) regenerating the plant cell into a plant; and
- iii) monitoring n-3 fatty acid production by said plant.

- 20 According to a further aspect of the invention there is provided a method for the production and optionally the extraction of n-3 fatty acids, in particular DHA, comprising:

- i) providing a cell according to the invention;
- 25 ii) providing conditions conducive to the growth of said cell; and
- iii) extracting n-3 fatty acids, or variants thereof, from said cell.

According to a yet further aspect of the invention there is provided a method for the production and optionally the extraction of n-3 fatty acid, particularly DHA,

30 comprising:

- i) providing a plant cell according to the invention;
- ii) regenerating said cell into a plant; and
- iii) extracting n-3 fatty acids, or variants thereof from said plant.

5 According to a further aspect of the invention there is provided n-3 fatty acids, particularly DHA, or variants thereof, obtainable by the method(s) according to the invention.

10 In a preferred embodiment of the invention said n-3 fatty acid, or variant thereof, is for use as a pharmaceutical.

In a further preferred embodiment of the invention said n-3 fatty acid, or variant thereof, is for use in the manufacture of a medicament for use in the treatment of conditions which would benefit from administration of n-3 fatty acids, or variant thereof.

15

In a preferred embodiment of the invention said condition is selected from the group consisting of: cardiac arrhythmia's; rheumatoid arthritis; Crohn's disease; schizophrenia; cancer; foetal alcohol syndrome; attention deficient hyperactivity disorder; cystic fibrosis; phenylketonuria; unipolar depression; aggressive hostility; adrenoleukodystrophy; coronary heart disease, hypertension, type II diabetes, ocular diseases.

20

According to a further aspect of the invention there is provided a non-human transgenic animal comprising at least one nucleic acid molecule according to the invention.

25

According to a yet further aspect of the invention there is provided a reaction vessel comprising at least one polypeptide according to the invention, fatty acid substrates and co-factors characterised in that said vessel is adapted for the conversion of said fatty acids substrates to n-3 fatty acids, in particular docosahexaenoic acid.

30

In a preferred embodiment of the invention said vessel comprises polypeptides having elongase, desaturase, acyl-CoA synthetase and diacylglycerol acyltransferase activities to provide a vessel in which at least part of a 3-n fatty acid biosynthetic pathway is reconstituted.

In a further preferred embodiment of the invention said polypeptides are those protein molecules disclosed herein. In particular, protein molecules which comprise the sequences as represented by Figures 1b, 2b, 3b, 3c, 4b, 5, 6b, 7b, 7d and 8b.

In a preferred embodiment of the invention said at least one polypeptide is expressed by a cell according to the invention.

In a preferred embodiment of the invention said polypeptide(s) is/are soluble. Alternatively said polypeptide(s) is/are immobilised.

In a further preferred embodiment of the invention said vessel is a bioreactor.

It will be apparent to one skilled in the art that a polypeptide according to the invention has utility with respect to the *in vivo* biosynthesis of n-3 fatty acids through transformation or transfection of nucleic acids encoding said polypeptide(s) into suitable host cells. Fatty acids can then either be extracted from said cells or foods comprising said cells can be eaten. Cells expressing said polypeptide (s) can also be incubated under suitable growth conditions to facilitate the synthesis of fatty acids. Alternatively, said polypeptide (s) can either be purified from an algal cell culture or manufactured recombinantly and used in a bioreactor to synthesise fatty acids *in vitro*. It will also be apparent that the invention involves, inter alia, the reconstitution of at least part of an algal n-3 fatty acid biosynthetic pathway which, either in a cell or *in vitro*, provides for a source of n-3 fatty acids which is an alternative to either the exploitation of algae in bioreactors or the consumption of fish.

An embodiment of the invention will now be described by example only and with reference to the following figures:

Table 1 represents fatty acid analysis of *P. lutheri* cells at two stages of growth.

5

Figure 1a represents the nucleic acid sequence of a nucleic acid molecule comprising a fatty acid elongase, *PIELO1*; Figure 1b the amino acid sequence comprising *PIELO1*;

- 10 Figure 2a represents the nucleic acid sequence of a nucleic acid molecule comprising a fatty acid elongase, *PIELO2*; Figure 2b the amino acid sequence comprising *PIELO2*.

- Figure 3a represents the nucleic acid sequence of a nucleic acid molecule comprising
15 fatty acid desaturase, *PIDES1*; Figure 3b the amino acid sequence comprising *PIDES1*; Figure 3c represents the full length amino acid sequence of *PIDES1*; Figure 3d represents the full length nucleic acid sequence of *PIDES1*.

- Figure 4a represents the nucleic acid sequence of a nucleic acid molecule comprising
20 fatty acid desaturase, *PIDES2*; Figure 4b the amino acid sequence comprising *PIDES2*;

Figure 5 represents a sequence comparison between the *Pavlova lutheri* proteins *PIDES1*, *PIDES2*, and the *Thraustochytrium* sp protein FAD4.

25

Figure 6a represents the nucleic acid sequence of a nucleic acid molecule comprising acyl-CoA synthetase, *PLACSI*; Figure 6b the amino acid sequence comprising *PLACSI*;

- 30 Figure 7a represents the nucleic acid sequence of a nucleic acid molecule comprising diacylglycerol acyltransferase, *PIDGAT2-1*; Figure 7b the amino acid sequence

comprising *PIDGAT2-1*; Figure 7c the full length sequence of a nucleic acid molecule encoding *PIDGAT2-1*; Figure 7d the full length amino acid sequence of *PIDGAT2-1* polypeptide; and

- 5 Figure 8a represents the nucleic acid sequence of a nucleic acid molecule comprising a fatty acid elongase, *PIELO1*; Figure 8b the amino acid sequence comprising *PIELO1*.

MATERIALS AND METHODS

Cultivation of *Pavlova lutheri*

Pavlova lutheri (CCAP 931/1) was obtained from the Culture Collection of Algae and Protozoa (Dunstaffnage Marine Lab., Oban, PA34 4AD, Scotland, U.K.).

- 15 The growth medium used in all experiments was enriched artificial seawater medium (EASW), made up in 20 l batches as described by Harrison et al. (1980), and modified by Thompson et al. (1991). The medium was further modified by increasing the macronutrient concentrations of NaNO_3 and $\text{Na}_2\text{SiO}_3 \cdot 9\text{H}_2\text{O}$ to 1 mM, and NaH_2PO_4 to 200 μM . The silicate was dissolved separately in deionized distilled water and the pH adjusted to approximately 8.0 with 50% HCl before it was added to the medium. This medium was buffered to pH 8.0 by adding 20 mM N-[2-hydroxyethyl]piperazine-N'-[2-ethanesulfonic acid] (HEPES) and 20 mM NaOH. The freshly prepared medium was filtered through a 0.22 μM Millipore™ GS membrane filter into a 20 l sterile propylene reservoir. It was then dispatched by 0.5 l in 1 l conical glass flasks and sterilized by autoclaving (30 min, 120°C). The batch cultures were grown at 15°C with 50 $\mu\text{E m}^{-2} \text{s}^{-1}$ constant illumination, and aeration provided by shaking the flasks at 150 rpm.

- 30 Cell density was monitored by counting cells with a haemocytometer. Since the *Pavlova lutheri* cells are motile, they were first incubated in sodium azide 20 mM to immobilise before counting.

The nitrate concentration was determined periodically during the culture time by measuring the change of the medium absorbance at 220 nm, according to the method described by Collos *et al.* (1999).

5

Isolation of total and poly(A)⁺ RNA from *P. lutheri*

The algal culture was harvested by centrifugation at 4,500 rpm for 15 min. The cell
10 pellet was suspended in 1 volume of extraction buffer (25 mM Tris-HCl pH 8.0, 25
mM EDTA pH 8.0, 75 mM NaCl, 1 % SDS v/v, 7.8 % β -mercaptoethanol v/v, in
DEPC treated water), and one volume of 25:24:1 phenol:chloroform:isoamyl alcohol
(v/v) was added. After 13,000 rpm centrifugation at 4 °C for 10 min, the aqueous
phase was transferred to a new tube and 1 volume of 24:1 chloroform:isoamyl
15 alcohol v/v added. After a second round of centrifugation, the upper phase was
transferred to a fresh tube and LiCl added to a final concentration of 2 M. This
solution was incubated for 1hr at -20 °C, and then centrifuged at 13,000 rpm at 4 °C
for 15 min. The resulting pellet was re-suspended in DEPC treated water and the
RNA was precipitated by addition of 0.1 volume of 3 M sodium acetate, pH 5.5 and
20 2.5 volumes of absolute ethanol followed by incubation for 20 min at 4 °C. This
sample was then centrifuged at 13,000 rpm at 4 °C for 15 min and the resulting pellet
was washed with 70 % ethanol, dried and re-suspended in DEPC treated water.
Quantity and quality of the extract were estimated by measuring optical density at
260 and 280 nm (1 O.D._{260 nm} = 40 μ g/ml RNA). An aliquot of the extract was also
25 visualised on a 1 % (w/v) agarose gel containing ethidium bromide.

For the cDNA library construction, poly(A)⁺ RNA was prepared with the Poly(A)
Quick® mRNA isolation kit (Stratagene) from cells harvested during the exponential
phase.

30

cDNA library construction and pBluescript phagemid excision

Double-stranded, end-adapted cDNA synthesised using a cDNA synthesis kit
5 (Stratagene) was passed through a Sepharose CL-2B gel filtration column
(Stratagene) to remove adapters and small cDNA molecules. cDNA eluted from the
column was phenol-extracted, ethanol-precipitated and ligated to arms of the Uni-
ZAP XR Vector (Stratagene) before packaging into λ phage using the Gigapack III
Gold Packaging Extract (Stratagene). A primary library of 3×10^6 plaque forming
10 units (pfu) was obtained with the majority of the inserts examined ranging from 0.3
to 1.5 kb. The library was subsequently amplified.

After amplification, the cDNA library was excised using the ExAssist™ Interference-
Resistant Helper Phage (Stratagene). The excised phagemids were plated as
15 individual bacterial colonies following the manufacturer's instructions. The presence
of insert was checked by PCR using universal primers and clones containing cDNA
longer than 0.2 kb were selected for sequencing.

Sequencing and sequence analysis

20 Sequencing reactions were prepared with the ABI Prism Big Dye-Terminator cycle
sequencing kit (PE Applied Biosystems), using the universal T3 primer, and these
were run on an ABI3700 (96-capillaries) sequencer (PE Applied Biosystems). The
resulting Expressed Sequence Tags (ESTs) were processed such that all vector
sequences were removed and further examined using standard nucleotide sequence
25 alignment algorithms in order to identify EST clones with overlapping sequences.
These overlapping sequences were then assembled into contigs. These contigs were
annotated by comparison with the non-redundant peptide and nucleotide databases
available from the National Centre for Biotechnology Information (NCBI). The
NCBI databases had been downloaded to a local Silicon Graphics Server which

allowed the annotation of thousands of ESTs to be performed as a batch job using the BLAST 2 sequence alignment algorithm (Altschul *et al.*, 1997).

The *PIELO1* *PIELO2*, *PIDES1*, *PIDES2*, *PIACSI* and *PIDGAT2-1* clones were
 5 identified on the basis of homology with other fatty acid elongase/desaturase/acyl-CoA synthase or diacylglycerol acyltransferase genes in the NCBI nucleotide and protein databases.

**Functional analysis of the *PIELO1* *PIELO2*, *PIDES1*, *PIDES2*, *PIACSI* and
 10 *PIDGAT2-1* ORFS by heterologous expression.**

Functional characterisation of the amino acid sequence encoded by *PIELO1* and *PIELO2* will be performed under protocols previously described (Jaworski *et al.*, 2001(or refer to as: US Patent No. 6,307,128);Qi *et al.*, 2002). To this aim, several species of fatty acid substrates will be considered: saturated (16:0, 18:0, 20:0, 22:0),
 15 monounsaturated (16:1, 18:1, 20:1) and polyunsaturated (20:4n-6, 20:5n-3, 22:5n-3) (figure 4).

Functional characterisation of the amino acid sequence encoded by *PIDES1* and *PIDES2* will be performed under protocols previously described (Qiu *et al.*, 2001).
 20 To this aim, several species of fatty acid substrates will be considered: saturated (16:0, 18:0), monounsaturated (16:1, 18:1) and polyunsaturated (18:2n-6, 18:3n-3, 18:3n-6, 18:4n-3; 20:2n-6, 20:3n-3; 20:3n-6, 20:4n-3, 20:4n-6, 20:5n-3, 22:4n-6, 22:5n-3 and 22:5n-6).

25 Functional characterisation of the amino acid sequence encoded by *PIACSI* will be performed under protocols previously described (Kang *et al.*, 1997). To this aim, several species of fatty acid substrates will be considered: saturated (8:0, 10:0, 12:0, 16:0, 18:0, 20:0, 22:0), monounsaturated (14:1, 16:1, 18:1) and polyunsaturated (18:2n-6, 18:3n-3, 18:3n-6, 20:4n-6, 20:5n-3 and 22:6n-3).

30

Functional characterisation of the amino acid sequence encoded by *PIDGAT2-1* will be performed under protocols previously described (Lardizabal *et al.*, 2001; Cases *et al.*, 2001, Zou *et al.*, 1999). To this aim, DGAT activity will be assayed by incorporation of [$1\text{-}^{14}\text{C}$] diacylglycerol into TAG in the presence of several species of
5 fatty acyl CoA substrates that are representative of fatty acids that partition to TAG in *P. lutheri*. These include: 14:0, 16:0, 16:1, 18:0, 18:1, 18:2, 18:4, 20:5 and 22:6.

TAG extraction and fatty acids analysis

10 The alga cells (2 ml of culture medium) were harvested during the experimental period by centrifugation at 13,000 rpm for 15 min. Fifty μg of tripentadecanoin (15:0-TAG) were added to the pellet as an internal standard. The pellet was then suspended in 1 ml of 2:1 chloroform:methanol (v/v) and frozen in liquid nitrogen. After 1 hour at 4°C , the cell debris was discarded by centrifugation and 0.3 ml of
15 0.9% KCl added to the supernatant. After centrifugation, the bottom phase was transferred into a 2 ml Ependorf and the KCl rinsed with 0.5 ml of chloroform. The chloroform phases were pooled and dried. The FA extract was suspended in 0.2 ml of hexane, and this volume was divided in 2 fractions of 0.1 ml. The first fraction was dried, and the lipid extract suspended in 0.2 ml of hexane. This represented the
20 total lipid extract. The second fraction was used to isolate the TAGs by hydrophobic chromatography. Bond Elut (Varian) 1 ml solid phase extraction columns with 100 mg Si packing were used to partition TAGs from other lipids in algal extracts. This protocol was adapted from a method described by Yongmanitchai and Ward (1992). The eluate was dried and the TAG extract suspended in 0.2 ml of hexane. The
25 products of these two extractions were analysed by GC as described previously by Larson and Graham (2001).

The same methodology will be employed to extract lipids and fatty acids from yeast cells in order to perform the functional analysis of *PIELO1* *PIELO2* and *PIDES 1*
30 following the feeding of different fatty acids as outlined above.

Fatty acid composition of *P. lutheri* cells

5

Table 1: Fatty acid composition (molar %) of *P. lutheri* cells at two stages of growth.

The important point to note from the data presented in table 1 is that *P. lutheri* does not produce 20:0, 22:0, 24:0, 20:1, 22:1 fatty acids but does produce 20:5n-3 and 22:6n-3. The amino acid sequence derived from the *PIELO1* gene as shown in Figure 2 has closest homology with *plant* elongases that are involved in the production of saturated and monounsaturated C20 and C22 fatty acids. *P. lutheri* does not produce such fatty acids. Therefore we conclude that the *PIELO1* gene product is involved in the production of 22:5 and 22:6 fatty acids which are found in *P. lutheri*.

15

Cloning and characterization of the genes *PIELO1*, *PIELO2*, *PIDES 1*, *PIDES 2*, *PLACS1* and *PIDGAT2-1*

The first pass sequencing of 5,719 cDNA clones from a cDNA library prepared from *P. lutheri* resulted in the identification of 34 cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with fatty acid elongase genes from a variety of organisms (Figure 3). This abundance of copies of the elongase gene indicates that it is expressed at a significant level in *P. lutheri* cells that are producing DHA and provides further proof that the *PIELO1* gene encodes an elongase 3-ketoacyl-CoA synthase polypeptide that catalyses the condensation of malonyl-CoA with acyl-CoA in the conversion of eicosapentaenoic acid to ω -docosapentaenoic acid which in turn is converted to docosahexaenoic acid.

The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of six cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with fatty acid desaturase genes from a

variety of organisms (Figure 2a and 2b). This elongase gene has been designated *PIELO2*.

5 The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of four cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with fatty acid desaturase genes from a variety of organisms (Figure 3a, 3b, 3c and 3d). This desaturase gene has been designated *PIDES 1*.

10 The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of three cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with fatty acid desaturase genes from a variety of organisms (Figure 4a and 4b). This desaturase gene has been designated *PIDES 2*.

15 The derived amino acid sequences from *PIDES 1* and *PIDES 2* both contain a histidine motif typical of fatty acid desaturase genes such as the $\Delta 4$ desaturase gene from the marine fungus *Thraustochytrium* sp. that is involved in the production of DHA and docosapentaenoic acid (Qiu *et al.*, 2001) (Fig.5).

20 The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of twelve cDNA clones from a single gene which gives a predicted amino acid sequence that has significant identity with acyl-CoA synthetase genes from a variety of organisms (Figure 6a and 6b). This acyl-CoA synthetase gene has
25 been designated *PIACSI*.

The sequencing of 5,719 cDNA clones from the *P. lutheri* library also resulted in the identification of one cDNA clone which gives a predicted amino acid sequence that
30 has significant identity with diacylglycerol acyltransferase 2 genes from several organisms (Figure 7a and 7b). This diacylglycerol acyltransferase 2 gene has been designated *PIDGAT2-1*.

The full length cDNA and protein sequence of *PIELO1* is disclosed in Figures 8a and 8b respectively.

5

REFERENCES

- 10 1. Uauy R, Mena P, Rojas C Essential fatty acids in early life: structural and functional role. *Proc Nutr Soc* 2000 Feb;59(1):3-15
2. Dewailly E, Blanchet C, Lemieux S, Sauve L, Gingras S, Ayotte P, Holub BJ. n-3 Fatty acids and cardiovascular disease risk factors among the Inuit of Nunavik.
15 *Am J Clin Nutr* 2001 Oct;74(4):464-73
3. Salem N *et al.* (1994) "Arachidonate and docosahexaenoate biosynthesis in various species and compartments in vivo." *World Review of Nutrition and Dietetics*, vol. 75, pp. 114-119.
- 20 4. Haag, M. Depressive Symptoms in Schizophrenia. *The Medicine Journal*, November 2001. Page 1-7.
- 25 5. Qi B, Beaudoin F, Fraser T, Stobart AK, Napier JA, Lazarus CM. Identification of a cDNA encoding a novel C18-Delta(9) polyunsaturated fatty acid-specific elongating activity from the docosahexaenoic acid (DHA)-producing microalga, *Isochrysis galbana*. *FEBS Lett* 2002 Jan 16;510(3):159-65
- 30 6. Ashford A, Barclay WR, Weaver CA, Giddings TH, Zeller S. Electron microscopy may reveal structure of docosahexaenoic acid-rich oil within *Schizochytrium* sp. *Lipids* 2000 Dec;35(12):1377-86

- 5 7. Hammond BG, Mayhew DA, Robinson K, Mast RW, Sander WJ. Safety assessment of DHA-rich microalgae from *Schizochytrium* sp. Regul Toxicol Pharmacol 2001 Jun;33(3):356-62
- 10 8. Simonpolous AP. Essential fatty acids in health and chronic disease. Am. J. Clin. Nutr. 1999;70 (3); 560S-569S.
9. Horrocks LA & Yeo YK. Health benefits of docosahexaenoic acid (DHA). Pharmacol. Res. 1999;40(3):211-
- 15 10. Collos, Y., Mornet, F., Sciandra, A., Waser, N., Larson, A., Harrison, P.J., 1999. An optical method for the rapid measurement of micromolar levels of nitrate in marine phytoplankton cultures. Journal of Applied Phycology 11, 179-184.
11. Harrison, P.J., Waters, R.E., Taylor, F.J.R., 1980. A broad spectrum artificial seawater medium for coastal and open ocean phytoplankton. Journal of Phycology 16, 28-35.
- 20 12. Larson, T.R. , Graham I.A., 2001. A novel technique for the sensitive quantification of acylCoA esters from plant tissues. The Plant Journal 25, 155-125.
13. Thompson, P.A., Harrison, P.J. , Parslow, J.S., 1991. Influence of irradiance on cell volume and carbon quota for ten species of marine phytoplankton. Journal of Phycology 27, 351-360.
- 25 14. Yongmanitchai, W., Ward, O.P., 1992. Separation of lipid classes from *Phaeodactylum tricornutum* using silica cartridges. Phytochemistry 31, 3405-340.
- 30 Broun P, Boddupalli S, Somerville C. 1998. A bifunctional oleate 12-hydroxylase: desaturase from *Lesquerella fendleri*. Plant J 13(2): 201-10

- Schnurr JA, Shockey J, Browse J. 2000 Characterization of an acyl-CoA synthetase from *Arabidopsis thaliana*. *Biochem Soc Trans.* Dec;28(6):957-8.
- 5 Kang MJ, Fujino T, Sasano H, Minekura H, Yabuki N, Nagura H, Iijima H, Yamamoto TT. 1997 A novel arachidonate-preferring acyl-CoA synthetase is present in steroidogenic cells of the rat adrenal, ovary, and testis. *Proc Natl Acad Sci U S A.* Apr 1;94(7):2880-4.
- 10 Qiu X, Hong H, MacKenzie SL. 2001 Identification of a Delta 4 fatty acid desaturase from *Thraustochytrium* sp. involved in the biosynthesis of docosahexanoic acid by heterologous expression in *Saccharomyces cerevisiae* and *Brassica juncea*. *J Biol Chem.* Aug 24;276(34):31561-6.
- 15 Cases S, Smith SJ, Zheng YW, Myers HM, Lear SR, Sande E, Novak S, Collins C, Welch CB, Lusi AJ, Erickson SK, Farese RV Jr. 1998. Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis. *Proc Natl Acad Sci U S A.* Oct 27;95(22):13018-23.
- 20 Hobbs DH, Lu C, Hills MJ. 1999. Cloning of a cDNA encoding diacylglycerol acyltransferase from *Arabidopsis thaliana* and its functional expression. *FEBS Lett.* 11;452(3):145-9.
- 25 Jako C, Kumar A, Wei Y, Zou J, Barton DL, Giblin EM, Covello PS, Taylor DC. 2001. Seed-specific over-expression of an *Arabidopsis* cDNA encoding a diacylglycerol acyltransferase enhances seed oil content and seed weight. *Plant Physiol.* 126(2):861-74.
- 30 Lardizabal KD, Mai JT, Wagner NW, Wyrick A, Voelker T, Hawkins DJ. 2001. DGAT2 is a new diacylglycerol acyltransferase gene family: purification, cloning,

and expression in insect cells of two polypeptides from *Mortierella ramanniana* with diacylglycerol acyltransferase activity. *J Biol Chem.* 19;276(42):38862-9.

5 Cases S, Stone SJ, Zhou P, Yen E, Tow B, Lardizabal KD, Voelker T, Farese RV Jr. 2001. Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members. *J Biol Chem.* Oct 19;276(42):38870-6.

10 Zou J, Wei Y, Jako C, Kumar A, Selvaraj G, Taylor DC. 1999. The *Arabidopsis thaliana* TAG1 mutant has a mutation in a diacylglycerol acyltransferase gene. *Plant J.* 19(6):645-53.

15

20

25

30

35

40

Claims

1. An isolated nucleic acid molecule comprising a DNA sequence selected from the group consisting of:
- 5
- i) the DNA sequence as represented in Figures 2a, 3a, 3d, 4a, 6a, 7a, 7c, and 8a ;
 - ii) DNA sequences which hybridise to the sequences identified in (i) above ; and
 - 10 iii) DNA sequences that are degenerate as a result of the genetic code to the DNA sequence defined in (i) and (ii)
2. An isolated nucleic acid molecule according to Claim 1 which anneals under stringent hybridisation conditions.
- 15
3. An isolated nucleic acid molecule according to Claim 1 or 2 which is isolated from an algal species.
- 20
4. An isolated nucleic acid molecule according to Claim 3 wherein said algal species is selected from the group consisting of: *Amphidinium carterae*, *Amphiphora hyalina*, *Amphiphora sp.*, *Chaetoceros gracilis*, *Coscinodiscus sp.*, *Crypthecodinium coohnii*, *Cryptomonas sp.*, *Cylindrotheca fusiformis*, *Haslea ostrearia*, *Isochrysis galbana*, *Nannochloropsis oculata*, *Navicula sp.*, *Nitzschia closterium*, *Pavlova*
- 25 *lutheri*, *Phaeodactylum tricornutum*, *Prorocentrum minimum*, *Rhizosolenia setigera*, *Skeletonema costatum*, *Skeletonema sp.*, *Tetraselmis tetrathele*, *Thalassiosira nitzschiioides*, *Thalassiosira heterophorma*, *Thalassiosira pseudonana*, *Thalassiosira stellaris*
- 30
5. A polypeptide encoded by a nucleic acid molecule according to any of Claims 1-4.

6. A polypeptide according to Claim 5 which is a variant polypeptide and comprises the amino acid sequence represented in Figure 2b, 3b, 3c, 4b, 6b, 7b, 7d, 5 or 8b which sequence has been modified by deletion, addition or substitution of at least one amino acid residue wherein said modification enhances the enzyme activity of said polypeptide.
7. A polypeptide according to Claim 5 wherein said polypeptide comprises the 10 amino acid sequence represented in Figure 2b, 3b, 3c, 4b, 6b, 7b, 7d or 8b.
8. A polypeptide according to any of Claims 7 wherein said polypeptide consists of the amino acid sequence represented in Figure 2b, 3b, 3c, 4b, 6b, 7b, 7d or 8b. 15
9. A vector including at least one nucleic acid molecule according to any of Claims 1-4.
10. A vector according to Claim 9 wherein said nucleic acid is operably linked to 20 a promoter.
11. A vector according to Claim 10 which promoter is an inducible promoter or a developmentally regulated promoter.
12. A cell transfected or transformed with at least one nucleic acid molecule 25 according to any of Claims 1-4 or at least one vector according to any of Claims 9-10.

- 13 A cell according to Claim 12 wherein said cell is transfected or transformed with nucleic acid molecules encoding elongase, desaturase, acyl-CoA synthetase and diacylglycerol acyltransferase activities to provide a cell in which at least part of a 3-
5 n fatty acid biosynthetic pathway is reconstituted.
14. A cell according to Claim 13 wherein said cell is transfected or transformed with nucleic acid molecules according to any of Claims 1-4.
- 10 15 A cell according to Claim 14 wherein said cell is transfected or transformed with nucleic acid molecules which comprise the sequences as represented by Figures 1a, 2a, 3a, 3d, 4a, 6a, 7a, 7c or 8a.
- 15 16. A cell according to any of Claims 12-15 which cell is selected from the group consisting of: mammalian cell (e.g Chinese Hamster Ovary cells); yeast cell (e.g. *Saccharomyces spp*, *Pichia spp*); algal cell (e.g *Phaeodactylum tricornutum*, *Chlamydomonas reinhardtii*); plant cell.
17. A cell according to Claim 16 which cell is a plant cell.
- 20 18 A plant comprising a cell according to Claim 17.
- 19 A plant according to Claim 18 wherein said plant is selected from the group consisting of: corn (*Zea mays*), canola (*Brassica napus*, *Brassica rapa*
25 ssp.), flax (*Linum usitatissimum*), alfalfa (*Medicago sativa*), rice (*Oryza sativa*), rye (*Secale cereale*), sorghum (*Sorghum bicolor*, *Sorghum vulgare*), sunflower (*Helianthus annuus*), wheat (*Triticum aestivum*), soybean (*Glycine max*), tobacco (*Nicotiana tabacum*), potato (*Solanum tuberosum*), peanuts (*Arachis hypogaea*), cotton (*Gossypium hirsutum*), sweet potato (*Ipomoea batatas*), cassava (*Manihot*
30 *esculenta*), coffee (*Coffea spp.*), coconut (*Cocos nucifera*), pineapple (*Ananas comosus*), citrus tree (*Citrus spp.*) cocoa (*Theobroma cacao*), tea (*Camellia sinensis*),

banana (*Musa* spp.), avocado (*Persea americana*), fig (*Ficus casica*), guava (*Psidium guajava*), mango (*Mangifer indica*), olive (*Olea europaea*), papaya (*Carica papaya*), cashew (*Anacardium occidentale*), macadamia (*Macadamia intergrifolia*), almond (*Prunus amygdalus*), sugar beets (*Beta vulgaris*), oats, barley, vegetables and
5 ornamentals.

20. A seed comprising a cell according to Claim 17 .

21 A cell according to Claim 16 wherein said cell is a yeast cell of the genus
10 *Saccharomyces* spp.

22 A cell according to Claim 21 wherein said yeast is *Saccharomyces cerevisiae*.

23. A foodstuff product comprising a yeast cell according to Claim 21 or 22.
15

24. A product according to Claim 23 wherein said product is selected from the group consisting of: wine; beer; baking products (e.g. bread, cake); dairy products; vegetable extracts.

20 25. A product according to Claim 24 wherein said wine or beer is non-alcoholic.

26. A fermentation process comprising a cell according to any of Claims 16 or 17 or Claim 21 or 22.

25 27. A fermentation process according to Claim 26 wherein said process comprises the steps of :

- i) providing a vessel containing a cell according to any of Claims 16 or 17 or Claim 21 or 22 and constituents required for fermentation and fatty acid biosynthesis; and
- 30 ii) providing conditions conducive to the fermentation of the liquid composition contained in said vessel.

28. An animal feed product comprising a cell according to any of Claims 12-17 or Claim 21 or 22.

5 29. A method of modulating the level of fatty acids, or variants thereof, in a plant cell comprising;

- i) providing a plant cell according to Claim 17;
- ii) regenerating the plant cell into a plant; and
- 10 iii) monitoring fatty acid production by said plant.

30. A method for the production and optionally the extraction of fatty acids comprising:

- i) providing a cell according to any of Claims or Claim 21 or 22;
- ii) providing conditions conducive to the growth of said cell; and
- 15 iii) extracting fatty acids or variants thereof, from said cell.

31. A method for the production and optionally the extraction of fatty acids comprising:

- 20 i) providing a plant cell according any of Claims 17;
- ii) regenerating said cell into a plant; and
- iii) extracting fatty acids, or variants thereof from said plant.

25 32. A non-human transgenic animal comprising at least one nucleic acid molecule according to any of Claims 1-4.

33. A reaction vessel comprising at least one polypeptide according to any of Claims 5-8, and fatty acid substrates characterised in that said vessel is adapted for
30 the conversion of fatty acids substrates contained therein.

34. A reaction vessel according to Claim 33 wherein said polypeptide is expressed by a cell according to any of Claims 12-17 or 21 or 22.

35. A reaction vessel according to Claim 33 or 34 wherein said vessel is a
5 bioreactor.

10

15

20

25

30

35

Figure 1a

CACGAGGCCCTCGTGCCGAATTCGGCACGAGGGCTGCGCGACGACAAGGAC
GACGGCAGCCTGAGTGCGACGAGCGATTTCTTCCGCTCGACGATCACGGA
TTGCGGCAATTTTGTGCGACGAGTCGGTCGACTTCCAGATGAAGCTTTTGTG
AGCGCAACCAGATCTCCGAGCGCTGCTACTTCCCACCTGGCATCCGCGCC
TACCGCAAGGGCGAGCGCGACTTTGACTTTTCGATGGCCGCCGCGCGCAA
GGAGTTCCGAGACTGTCTGCTTTCACGACCGTCGACGAGCTGTCTGCGCAAGA
CGGGCGTAAAGCCGCGAGATATCGACATCCTCGTCGTCAACTGCTCGCTC
TTCAACCCGACGCCATCGCTGGCTGCGATCGTGATCAACCACTACCAGAT
GAAGGACTCCGTACAGAGCTACTCACTTGGCGGGATGGGTGCTCAGCGG
GACTCATCTCAATCCACCTCGCAAAGGACCTGCTGCAGGTCTACCCGCGC
AAGCGCGCGCTCGTCATCTCGACGGAGAATCATCGCAAAATTTTACCA
GGGCAACGAAAAGTCGATGCTCATCTCGAACACGCTCTTCCGAATGGGCG
GCGCCGCGTCTCTCTTCCGCGCGCCACGCCGACCGCGCGCTCGCCAAG
TATCAACTGCTGCACACCGTCCGCGACGCAAGGGCGCGGACCCGCGACGC
GTACCGGTGCGTCTTCCAGGAGGAGACAAGGCGGGGCGACGTGGGCGTGC
GCCTGTGCAAGACGTGATGGAGTGCGCCGCGCGCGCGATGAAGACCAAC
ATCTCCGTCTCTCGCGCTCTGATTCTGCGCGTTTCTGAGCAGGTCCGATT
TCTCGCAAACTACGTTGCGCGCAAGTGGCTGCGAATGAAAGGCGTGAAGG
GATACGTGCCCGGACTTCACAACGGCCGTGCAGCACTTTTGCATCCACACG
GGCGGGCGCGCGGTGCTCGACGCGCTGCAGGCGAACTTGTGCTCTCAGA
TTACTACCTCGAGCCGAGCCGTTACTCCCTGTGGCGCTGGGGTAACGTCT
CAAGCGCTCAGTCTGGTACGAGCTCGACTGGCTCGAAAAGTCCGCGCGC
ATCCGCGCGGGCGACAAGGTGTGGCAGATTGGGTTTGGCAGCGGCTTCAA
GTGCAACTCGGCCGCTGTGGCGGGCGTGCCGAGCGATGCCCTAGCTACGCC
GGCGCCGTCCGCATTGCCAGTGGTTTCGTGACAGACAGTCACACTGACGAG
TGCGGAGTGACGTCTGACGCCTTCCCCCCCCCGCCACCACTCCACCTC
CAGCTCCTTCACTCTCACTCAATCGCGCGGCGGCCAGAGCAGGAGCGCGC
TCGTGCTCGCCATCACCGCCTTGTAAGTCTCTCGCGCGCTCGAGCGAGCGC
GCGTCCATGAGCGGCACGGACGCGAAGCGGAAGAAGAGCCACATCACAGC
AGAAAAAAAAAAAAAAAAAACTCGAGACTAGTTCTCTTACCGCGCTGC
CGAGCTCAAGCACGGCCGCGTGTGCATGCTCGCCGTCACCGGCATGCTTG
TCCAGGAGGTGTACTCGTGCCGGCACCCGACGGCGTCTTCAAGGCGCCG
ACGCCGCTCGGCGCGCTCTCGACCGTGCCGGCGCTCGGCCCTCATCCAGCT
CATCGTCTTCTCGGCATCATCGAGGTGCGCTCGGCCAACTACCAGGGCC
CGGTGCCCCGGCGACCTTGGCTTTGACCCGCTCGG

Figure 1b

R G L V P N S A R G L R D D K D D G S L S A T S D F F R S T I T D C G N F C D E
S V D F Q M K L F E R N Q I S E R C Y F P P G I R A Y R K G E R D F D F S M A A
A R K E F E T V V F T T V D E L L A K T G V K P R D I D I L V V N C S L F N P T
P S L A A I V I N H Y Q M K D S V Q S Y S L G G M G C S A G L I S I H L A K D L
L Q V Y P R K R A L V I S T E N I T Q N F Y Q G N E K S M L I S N T L F R M G G
A A V L L S G R H A D R R V A K Y Q L L H T V R T H K G A D P D A Y R C V F Q E
E D K A G H V G V R L S K D V M E C A G A A M K T N I S V L A P L I L P V S E Q
V R F L A N Y V A R K W L R M K G V K G Y V P D F T T A V Q H F C I H T G G R A
V L D A L Q A N L S L S D Y Y L E P S R Y S L W R W G N V S S A S V W Y E L D W
L E K S G R I R R G D K V W Q I G F G S G F K C N S A V W R A C R A M P

Figure 2a

GCACGAGGCCTCGTGCCGAATTCCGGCACGAGGCGGCGCTGTGGTCTGGT
TACCGACGTACGACGAGTTTGTCTGATGGGCTTTTCGTTCGTTCGACCGCGAG
AAGATCGGCGTGACATGGTTCGACACGAGGCGTGATTACCTCTGCGGAGTG
GGCGGCCATCTCGGTCGACAAGCACATGTCCTTCTTCTCCGACGCGGCCG
AGTTCACGGGCGACCACTGGATCATCCCGCTCGTCGCGGTTCGCACTCTAC
CTCGTGATGATCGTCGTTCGGCCCAATGATCATGGCCAACCGGCCGCGCT
CCCCGTGAATGGGCTCGCCTGCGCGTGGAACGGTTCCTGGCCGCAATTCA
GCACTTTTCGGCGTGGCTTGACAGTGGCACTGTATCTTACCAGGCTGCGT
AGCCGCGGCTTCGAGAGCACGACGTGCGGCGAGCGCCATGTTTCATGTCGCA
GGGGTACGTTGGCTTGGCAATGCTGCTCTTCATCTACTCCAAGCTCTTCG
AGTTGATCGACACCTTCTTCTCATCGCGAAGAAGGCGGATGTGATCTTC
CTGCATTGGTACCACACGTACCGTGCTGCTCTACTGCTGGCACTCGCA
CTCGGTCCGGATACCGAGCGGGATCTGGTTCGCGCGATGAACACTTTG
TGCACGCCATCATGTACTCCTACTTTGCGATGACGCAGATGGGTCCGCGC
TACCGCAAGCTCGTCCGGCCGTACGCGCGGCTGATTACGACCCCTGCAGAT
CTCGCAGATGTTTCGTCGGCCTCATCGTCAACGGCTCGATCATTTACTTCA
CGTCGCTCGGGCACGCATGCAAGTCGAGCAAGACGAACACGATCCTGAGC
TGCTGATGTACCTCAGCTACTTTGTGCTATTTCGACTGCTCTACCTGCG
CAATTACATCCTTGGTACACATGGCAAGCCGCGGGCAAGCGCGCAAAGG
GCAAGGCGGAATAGTGCAGGGCCGGGGAGGCGGTGCCCAACCGCGCTCG
CAAAGCGGTCGCGCTCCTTGCCGAGATGCGACGAGAGTCGAAGAGGTGAA
ACCTCCTTAAATAATGCTACTCCTAGATTTTCGCTTTGTGCTTCCGTAT
AGATGGTCAAGCC

Figure 2b

H E A S C R I R H E A A L W S W L P T Y D E F V D G L S F V D R E K I G V H M V
D Q G V I T S A E W A A I S V D K H M S F F S D A A E F T G D H W I I P L V A Y
A L Y L V M I V V G P M I M A N R P P L P V N G L A C A W N W F L A A F S T F E
V A C T W H C I F T R L R S R G F E S T T C G S A M F M S Q G Y V G L A M L L F
I Y S K L F E L I D T F F L I A K K A D V I F L H W Y H H V T V L L Y C W H S H
S V R I P S G I W F A A M N Y F V H A I M Y S Y F A M T Q M G P R Y R K L V R P
Y A R L I T T L Q I S Q M F V G L I V N G S I I Y F T S L G H A C K S S K T N T
I L S W L M Y L S Y F V L F G L L Y L R N Y I L G T H G K P A G K R A K G K A E

Figure 3a

CACGAGGCGAATGTGGGCGGCTACTGGCTTGGCGTGCTCAATGGAGGGCT
CAACTTCCAGATCGAGCACCATCTTTTCCGCGGCTGCACCATTCTACT
ACGCGCAGATTGCCCCAGTGGTGCGCACGCACATCGAGAAGCTCGGCTTC
AAGTACAGGCACTTCCCCACGGTGGGCTCCAATTGTTCGTCCATGCTGCA
GCACATGGGCAAGATGGGCACTCGCCAGGAGCTGAGAAGGGCGGCAAGG
CCGAGTGAGCTGCCGCCCTACCCTGCCTCTGCGGCTAGCCAGCAACCGGG
TGCCAGCGAGCCCCCTCTTCCATCCGAGCCCTTTTCTCCTTCACCCTGCCA
TGTGTCAGCGGCACTGACTGAACTGACGTCGCCGTGCCGCTGGCGCTCTC
CGTCGCCAGCCACTGAGAGGCTGCAATGCCGCCCGACGCCGCTCACGCGG
CTTTGGTCTTAAAAAAAAAAAAAAAAAAAA

Figure 3b

H E A N V G G Y W L G V L N G G L N F Q I E H H L F P R L H H S Y Y A Q I A P V
V R T H I E K L G F K Y R H F P T V G S N L S S M L Q H M G K M G T R P G A E K
G G K A E

Figure 3c

MPPSAASEGG VAE LR AAEVA SYTRKAVDER PDLTIVGDAV YDAKAFRDEH PVGAHFVSLF
GGRDATEAFM EYHRRTWPKA RMSKFFVGSL DASEKPTQAD SAYLR LCAEV NALLPKGSGG
FAPPSYWLKA AALVVAAVSI EGYMLLRGKT LLLSVFLGLV FAWIGLNIQH DANHGALSRH
SVINYCLGYA QDWIGGNMVL WLQEHVVMHH LHTNDVDADP DQKAHGVLRL KPTDGWMPWH
ALQQLYILPG EAMYAFKLLF LDALELLAWR WEGEKISPLA RALFAPAVAC KLGFWARFVA
LPLWLQPTVH TALCICATVC TGSFYLAFFF FISHNFDGVG SVGPKGSLPR SATFVQRQVE
TSSNVGGYWL GVLNGGLNFQ IEHHLFPR LH HSYYAQIAPV VRTHIEKLGF KYRHFPPTVGS
NLSSMLQHMG KMGTRPGA EK G GKAE

Figure 3d

ACGCGGTGTACGCGCGTCTTCCAGCGCGAGCCGCTGCTCCGCGCGAAGTCTCTAGGCATGCCGCTTCGGCCGCGAGCGAGGGCGGC
GTGGCGGAGCTGCGCGCGGCGGAGGTGCGCTCGTACACGCGCAAGGCGGTGGATGAGCGCCCGACCTCACCATCGTCGGCGATGCCGT
CTACGACGCCAAGGCCCTTCCGTGACGAGCACCCGGTCGGCGCCCACTTTGTGAGCCTCTTTGGCGGGCGGACGCGACCGAGGCGTTCA
TGGAGTACCACCGGCGGACGTGGCCCAAGGCGCGGATGAGCAAGTTCTTCGTGGGCTCGCTCGACGCTCCGAGAAGCCGACGCGAGGCC
GACAGTGCTTACCTCCGGCTGTGCGCGGAGGTGAACGCCCTTGCTGCCAAGGGGAGCGGCGGCTTTGCGCCGCCCTCTATTGGCTCAA
GGCGGCGGCGCTGGTGGTGGCCGCCGTGTGATTTGAGGGGTATATGCTGCTGCGCGGCAAGACGCTCCTCCTCTCGTCTTTCTCGGCC
TCGTCTTTGCGTGGATCGGTCTCAACATCCAGCACGACGCGAACCACGGCGCGCTCTCGCGCCACTCGGTGATCAACTACTGCCCTTGGG
TACGCGCAGGACTGGATCGGCGGCAACATGGTGTCTGGCTGCGAGGAGCAGTGGTGTATGCCACCTGACACCAACGACGTGACGCG
CGACCCGGACCAAGGCGCACGGCGTGTGCGGCTCAAGCCAAAGGACGGCTGGATGCCGTGGCATGCGCTCCAACAGCTTTACATTC
TGCCCGCGAGGCGATGTACGCTTTAAGCTGCTCTTCTCGACGCGCTCGAGCTGCTCGCGTGGCGATGGGAGGGCGAGAAGATCTCG
CCCCCGCGCGGCCCTGTTTGCACCGCGGTGGCGTGCAAGCTTGGCTTCTGGGCGCGCTTCGTGCGGCTGCGGCTCTGGCTGCGAGCC
GACGGTGACACCGGCGCTGTGCATCTGCGCGACGGTGTGACGCGGCTCCTTCTACCTCGCCTTCTTCTTCTCATCTCGCAAACTTTG
ACGGCGTGGGTAGTGTGGGCCCCAAGGCGAGCTTGCCGCGCTCTGCAACCTTCGTGCGCGGCGAGTCCGAGACGAGTTGAAATGTGGG
GGCTACTGGCTTGGCGTGTCAATGGAGGGCTCAACTTCCAGATCGAGCACCATCTTTTCCGCGGCTGCACCATTCGTACTACGCGCA
GATGCCCCAGTGGTGTGCGCACGCACATCGAGAAGCTCGGCTTCAAGTACAGGCACTTCCCACGGTGGGCTCCAACCTGTGCTCCATGC
TGCAGCACATGGGCAAGATGGGCACTCGCCAGGAGCTGAGAAGGGCGGCAAGGCCGAGTGAAGTGTGCGGCCCTACCTGCGCTCTGCGG
TAGCCAGCAACCGGGTGCCAGCGAGCCCTCTTCCATCCGAGCCCTTTTCTCCTTCACTGCGCATGTGTCAGCGGCACTGACTGAACT
GACGTGCGCGTGCCGCTGCGGCTCTCGTCCGCGCCACTGAGAGGCTGCAATGCCGCGCGACGCGGCTCACGCGGCTTTGGTCTTAAA
AAAAAAAAAAAAAAAA

Figure 4a

GCACGAGGGTGCTGCTACCTGCTGTACGTCTCCCTCGGCTCGATGTACAT
CTTCTGCAACTTTGCCGTGTGCGACACGCACCTGCCCATCGTTGAGGCCG
ACCAGCACGCCACCTGGGTTGAGTACTCGGCCAACCACAGACCAACTGC
GCGCCCTCGTGGTGGTGCGACTGGTGGATGTCTTACCTCAACTACCAGAT
CGAGCATCATCTGTTCCCGTCCATGCCGCAATTCCGCCACCCGACGATCG
CGCCGCGCGTCAAGGCGCTCTTCGAGAAGCACGGGCTGCACATGACGTG
CGCGGCTACTTTGAGGCGATGGCCGACACGTTTCATGAACCTTGACAAGGT
CGGCAACGCGCACGAGCACCAACCATTAGGCCGTAGCCGCTTGAAAAGAGG
CCTCCTGCATACGCGGCGACGCGTCGGCGCGCGGCGGCGTGCACGGGAGC
ACAAAGTGATGGATGGACCTTGGGCGACGCCGACGGCCAAGGAGTGTTG
TCTCTGTCGTCGCCAGGGCCCAGGAGCCCAGGGGCAGGGTTGCAGAGCTT
GGGCGCGATTGGAGGCAGGGCCGGGCGCGTCCGCGTTCGCGAGTCTGGCG
AGGCGCTCTGCGAGCTCTGCACGACTGCGCCCAGAGGCGTGCAGCGCGCGC
GCGAGTTCCAAAAAAAAAAAAAAAAAAAAA

Figure 4b

A R G C C Y L L Y V S L G S M Y I F C N F A V S H T H L P I V E A D Q H A T W V
E Y S A N H T T N C A P S W W C D W W M S Y L N Y Q I E H H L F P S M P Q F R H
P T I A P R V K A L F E K H G L H Y D V R G Y F E A M A D T F M N L D K V G N A
H E H N H

Figure 5

TspFAD4	MTVGYDEEIPFEQVRAHNKPDDAWCAIHGHVYDVTKPASVHPGGDIILLAGKEATVLYET
PlDES1	-----
PlDES2	-----
TspFAD4	YHVRGVSDAVLRKYRIGKLPDGGQGANSEKERTLSGLSSASYTTWNSDFYRVMRERVVAR
PlDES1	-----
PlDES2	-----
TspFAD4	LKERGKARRGGYELWIKAFLLLVGFWSLYWMCTLDPSFGAILAAMSLGVFAAFVGTCTIQ
PlDES1	-----
PlDES2	-----
TspFAD4	HDGNHGAFQAQSRWVNKVAGWTLDMIGASGMTWEPQHVLGHHPYTNLIEEENGLQKVSGKK
PlDES1	-----
PlDES2	-----
TspFAD4	MDTKLADQESDPDVFSTYPMRLHPWHQKRWYHRFQHIYGPPIFGFMTINKVVTQDVGUV
PlDES1	-----
PlDES2	-----
TspFAD4	LRKRLFQIDAECRYASPMYVARFWIMKALTPLYMVALPCYMQGPWHGLKLFALAHFTCGE
PlDES1	-----
PlDES2	-----
TspFAD4	VLATMFIVNHIIEGVSYASKDAVKGTMAPPKTMHGVTMNNTRKEVEAEASKSGAVVKS
PlDES1	-----
PlDES2	-----ARGCCYLLYVSLGSMYIFCNFAVSHTHLP
TspFAD4	PLDDGWAVVQCQTSVNWSVG-SWFWNHFSGGLNHQIEHHLFPGLSHETYYHIQDVFQSTC
PlDES1	-----HEANVG-GYWLGVINGGLNFIHHLFPRLHHSYYAQIAPVVRTHI
PlDES2	EADQHATWVEYSANHTTNCAPSWWCDWMSYLNQYIEHHLFSPMPQFRHPTIAPRVKALF
TspFAD4	AEYGVVPYQHEPSIWTAYWKMLEHLRQLGNEETHESWQRAA
PlDES1	EKLGFKYRHFPFTVGSNLSSMLQHMGRMGTRPGAEGGKAE
PlDES2	EKHGLHYDVR-GYFEAMADTFMNLDRVGNAAHEHNH-----

Figure 6a

GCACGAGGCTCTTCGGCTGGGCGCTCGACGACGCGCTCGCCAAGTATGA
 CAAGGGCGGCGTCCGCCCCGGCTTCTGTACAACGCGGTCGTCTTCTCGT
 CGGTGCAGGCGCTGCTCGGCGGTGCGGTGCGCATGATGGTCGCCGCTCC
 GCGCCCCCTCTCCGCCGACGTGCAGAAGTTTGTGCAATCGTGTCTCAACGC
 GCCGCTTCGCCAAGGCTACGGCCTCACCGAGACGTGCGCGGCGACGACGC
 TCTGCGCGCTGCACGACAACACGCCGTGCAAGTTGGGCGCGCGCAGGAG
 TCGGCGTGATCACGCTGCGCGACTGGGAGGAGGGCAACTACCGCAACCG
 CGACGCCAACGACCCGGCCATCGGGATGCGGCGCGGCGAGATCCTGATCG
 GTGGGCCCCGCGTCTGCCTCGGCTACTACGTGAACGAGCGCGCGCCGAC
 GCGGACGTGGTGAAGCGCAACGCGGAGGACTTTGTGACGATCAACGGCAT
 GCGCTTCTTCTGCTCGGGCGACATCGGCCAGATCACGCCGAGCGGCTGCG
 TGCAGATTATCGACCGGAAGAAGGACCTCGTCAAGCTGCAGCAGGCGGAG
 TACGTGCGGCTCTCAAGGTGGAGAACGCGCTCAAGAACTCGTCGTACAC
 GCAGATCCCGTACGTCTACGCGCTCTCATCCAAGAGCTACTGCATCGCGC
 TCCTCTGCCCGCAGCACGCGGCGATCCGCCAGCTCGCCGCTCGCTGCAG
 ATCAGCGGCAAGGAGCTTTCGAGCTGTGCGCGCACCCGCGAGATCGTCGC
 GGCCGTGCTCAAGGACCTGCAGGCGCAGTGCAAGGCGGCCAAGCTCGCGG
 GCTTCGAGACGCCGAGCAAGCTCATCCTCGTGTGCGGACGAGTGGACCGTT
 GAGAATGACATGCTCACACGACGATGAAGATCAAGCGCAAGCCAATCGC
 TGACCGGCACGCGAGCGAGATCAAGGCCGTTTACGTCTGAGCCCGCGCCT
 TTTTGTACAACCTCGAGAGCGCCACTGTCTTGATGGCGCGCGCTGCTGT
 TGTGCGAGGCGCTCGGCATTGACCGCGGCGCTTGAACGCAAGGCAGGCGCA
 AGGCGCGGAGGGATTGCTGGGGATGGCGGCTGCCGCGATTGCTGAGCAG
 AAGGCAGTCTCCGGCTCTCGACAGGTGGCGCCCGTTGTGAGAATGTTCCG
 CAGCCCCCTCCCCCTCGGGCGGCTGCCATTGCGGGCAGCGCTCGCACATG
 TGCTGCGCTCCGCGAGCCGACGCCACGGCCACCAACGCGTGTGCTGCGG
 TCACGCGCGCGCCCCGTGGGAACGACCGTTGCCCTCGCAC

Figure 6b

A R G L F G W A L D D A L A K Y D K G G V G P G F L Y N A V V F S S V Q A L L G
 G R V R M M V A G S A P L S A D V Q K F V Q S C F N A P L R Q G Y G L T E T C A
 A T T L C A L H D N T P S Q V G P P Q E S A C I T L R D W E E G N Y R N R D A N
 D P A I G M R R G E I L I G G P A V C L G Y Y V N E R A P D A D V V K R N A E D
 F V T I N G M R F F C S G D I G Q I T P S G C V Q I I D R K K D L V K L Q Q G E
 Y V A L S K V E N A L K N S S Y T Q I P Y V Y A L S S K S Y C I A L L C P Q H A
 A I R Q L A A S L Q I S G K E L S E L C A H P Q I V A A V L K D L Q A Q C K A A
 K L A G F E T P S K L I L V S D E W T V E N D M L T T T M K I K R K P I A D R H
 A S E I K A V Y V

Figure 7a

GCACGAGGGCTCGACCTACTGCCCCGCGCTGCGCGGCAAGATGCGCTGGCT
CGCGGCGAGCGTGCTCTTTTCGGCTTCCCATCGTGCGCGAGCTCACCCTTT
GGACCGGCTGCATCGACGCGCGCCGCTCGGTTGCCGAGAGTGCGCTGCGT
GGCGGCTACTCAGTCGGCGTACTGCCCCGGCGGCGAGCAGGAGCAGCTGCG
CACGCGCTACGGGCGCGAGTCGGTATATTTGCGCAAGCGCTTTGGCTTCG
TCAAGCTTTCGCTCCGCTTCGGCGTGCCGCTCGTGCCCTGGGTACGTGTTT
GGGTGCGTCGACCTGTACCACACTTCATCCCTGCTCTTCTCGGCGCGCGA
GTGGCTCGTGCGCTCTCTCGGCGTGTCGTGCGCGTGTGCTTCGGAGCGT
GGGGCGTGCCCATGGCGCCGCTTGCTGTGCCGCTCAACGTCGTGATCGGC
CGGCCGATCAAGCTGCCGCGCAACCCTGAGCCGACCGATGAGGACGTCGC
GCGCGCGCTCGACCAGTACATCGCCGCGCTGCGCGCGCTCTTTGACGAGA
ACAAGGCGCGCTTTGGCTATGCCGACCGCGAGCTGGAGGTGTGCTGATTG
TGAAGAAGTGTCATTGAAGGTCGGCGTCAGCAGGCGCACCGCGCACCAAG
CCACTCACGTCTTGATCGCTGAACCGCCGTGAACGATGCCGTTGCGACAC
GCTTGAAGATGGCCAGAAAAAAAAAAAAAAAAA

Figure 7b

A R G L D L L P A L R G K M R W L A A S V L F R L P I V R E L T L W T G C I D A
R R S V A E S A L R G G Y S V G V L P G G E Q E Q L R T R Y G R E S V Y L R K R
F G F V K L A L R F G V P L V P G Y V F G C V D L Y H T S S L L F S A R E W L V
R S L G V C V P V C F G A W G V P M A P L A V P L N V V I G R P I K L P R N P E
P T D E D V A R A L D Q Y I A A L R A L F D E N K A R F G Y A D R E L E V C

Figure 7c

ACTGCGTGTACACAGCATGGCGGCTCGCGCGGTTGACGCGCTCGTCGTGAGCGCGTTTAC
GGCGTTTCGTGCAGATCGGCGTGTGGGCGCTCACGCCCGTGGGCATTGCGTGGGCCCTCGC
GTTCCACTGGAAGGTGACGCTGCCGCTGCTCGCCCTTTATCTCGCGTCGTACCTCGACGG
CGCCGAGGTGCGCGTCAAGCGCGTGC CGCGTGGCCGGCGTTCTCCCGGCATTTTGGCT
GTTACGTTTCATGCGCAGGGTCTACCGGCAGCGCGTTCACGTGCCAGCTGGCCTCGAGGC
CGAGGAGCAGATCATCCTAGCGCTGCATCCGCACGGCTCGATGGCGGACTACCGCGCGAT
CCTCGACGGCCAGCTGCTCGACCTACTGCCCGCGCTGCGCGGCAAGATGCGCTGGCTCGC
GGCGAGCGTGCTCTTTTCGGCTTCCCATCGTGCGCGAGCTCACCTTTGGACCGGCTGCAT
CGACGCGCGCCGCTCGGTTGCCGAGAGTGCCTGCGTGGCGGCTACTCAGTCGGCGTACT
GCCC GGCGGCGAGCAGGAGCAGCTGCGCACGCGCTACGGGCGCGAGTCGGTATATTTGCG
CAAGCGCTTTGGCTTCGTCAAGCTTGCGCTCCGCTTCGGCGTGCCGCTCGTGCTGGGTA
CGTGTTGGGTGCGTCGACCTGTACCACTTCATCCCTGCTCTTCTCGGCGCGCGAGTG
GCTCGTGCGCTCTCTCGGCGTGTGCGTGCCCGTGTGCTTCGGAGCGTGCGGCGTGCCCAT
GGCGCCGCTTGCTGTGCGCTCAACGTGCTGATCGGCCGGCCGATCAAGCTGCCGCGCAA
CCCTGAGCCGACCGATGAGGACGTGCGCGCGCGCTCGACCAGTACATCGCCGCGCTGCG
CGCGCTCTTTGACGAGAACAAGGCGCGCTTTGGCTATGCCGACCGCGAGCTGGAGGTGTG
CTGATTGTGAAGAAGTGTCAATTGAAGTTCGGCGTCAGCAGGCGCACCGCGCACCAGCCA
CTCACGTCTTGATCGCTGAACCGCCGTGAACGATGCCGTTGCGACACGCTTGAAGATGGC
CAGAAAAAAAAAAAAA

MAARAVDALV VSAFTAFVQI GVWALTPVGI AWALAFHWKV TLPLLALYLA SYLDGAEVRV
KRVRAWPAFS RHFWLFTFMR RVYRQRVHVP AGLEAEEQII LALHPHGSMA DYRAILDGQL
LDLLPALRGK MRWLAASVLF RLPIVRELTl WTGCIDARRS VAESALRGGY SVGVLPGGEQ
EQLRTRYGRE SVYLRKRFGF VKLALRFGVP LVPGYVFGCV DLYHTSSLLF SAREWLVRSL
GVCVPVCFGA WGVPMAPLAV PLNVVIGRPI KLPRNPEPTD EDVARALDQY IAALRALFDE
NKARFGYADR ELEVC

Table 1 : Fatty acid composition (molar %) of *P. lutheri* cells at different stages of the growth cycle. Each value represents the mean \pm SD of two replicate from one flask.

Fatty acids	Exponential phase		Stationary phase	
	189 h ^a	285 h	353 h	452 h
<i>In total extract</i>				
14:0:	12.19 \pm 2.08	11.33 \pm 0.44	11.07 \pm 0.12	11.08 \pm 0.03
16:0	26.05 \pm 2.93	21.62 \pm 0.61	16.40 \pm 0.20	25.26 \pm 0.17
16:1n-7	21.92 \pm 3.60	23.78 \pm 1.34	20.28 \pm 0.29	27.56 \pm 0.37
18:0	8.27 \pm 0.90	3.48 \pm 0.35	2.93 \pm 0.13	1.39 \pm 0.24
18:1n-9	ND ^b	0.93 \pm 0.08	8.22 \pm 0.12	2.32 \pm 0.07
18:2n-6	ND	2.43 \pm 0.15	2.33 \pm 0.02	3.66 \pm 0.03
18:3n-3	ND	ND	ND	0.38 \pm 0.01
18:4n-3	ND	4.72 \pm 0.20	5.81 \pm 0.11	4.39 \pm 0.03
20:3n-3	ND	ND	ND	0.27 \pm 0.01
20:5n-3	13.94 \pm 1.48	14.44 \pm 0.73	15.21 \pm 0.39	14.87 \pm 0.23
22:6n-3	8.62 \pm 1.74	7.90 \pm 0.43	7.35 \pm 0.15	5.89 \pm 0.03
<i>In TAG extract</i>				
14:0	11.93 \pm 0.08	6.96 \pm 0.66	6.83 \pm 0.03	7.63 \pm 0.18
16:0	43.04 \pm 1.59	22.94 \pm 0.76	20.16 \pm 0.70	29.74 \pm 0.95
16:1n-7	37.70 \pm 2.23	33.52 \pm 5.12	39.39 \pm 3.10	37.40 \pm 1.42
18:0	ND	1.52 \pm 2.15	0.62 \pm 0.87	0.91 \pm 0.53
18:1n-9	ND	2.66 \pm 2.28	0.60 \pm 0.85	3.40 \pm 0.10
18:2n-6	ND	7.93 \pm 4.31	3.33 \pm 1.66	6.15 \pm 0.31
18:4n-3	ND	ND	ND	0.92 \pm 0.16
20:5n-3	7.33 \pm 0.73	6.02 \pm 1.07	5.31 \pm 0.16	8.50 \pm 0.42
22:6n-3	ND	3.69 \pm 0.91	3.31 \pm 0.64	1.97 \pm 0.07

^a, time of incubation.

^bND, Not detected.

Figure 8a

GGCACGAGGGGGAGATGGCGGCGCCGACATCGCCGTACGGCGCGGAATCGCCGCGCGGGCGTACGCGTAC
CCGGAGCGTGCAAATGTCAAGATGTCCGAGGCGCTGCGCGTACTCGACGAGGGCGTGACCCGCTCGTTAT
TCACAGCTCGCAGATCCTCGCCGCGCGCTGCTCGTCACGGCCGCGCTCAACCACTTTCCCAAGATCACCG
TCGCGGACCTCGCCGAGATCTGGCGCTCGCTGCAGATCGACGTGGCGTACGCGTTTCGCGCTGACTGCGGTG
GCCGTGCTGCTTCTCGGCTACTACGCTCTCCGCCACCCGCGCCCCGTCTACCTCGTCGACTTCGCCACGTG
GCAGCTGCGCGACGACAAGGACGACGGCAGCCTGAGTGCGACGAGCGATTCTTCCGCTCGACGATCACGG
ATTGCGGCAATTTTTCGACGAGTCGGTCGACTTCCAGATGAAGCTTTTTCGAGCGCAACCAGATCTCCGAG
CGCTGCTACTTCCCACCTGGCATCCGCGCCTACCGCAAGGGCGAGCGCGACTTTGACTTTTCGATGGCCGC
CGCGCGCAAGGAGTTTCGAGACTGTCTCTTACGACCGTCGACGAGCTGCTCGCCAAGACGGGCGTAAAGC
CGCGAGATATCGACATCCTCGTCTCAACTGCTCGCTCTTCAACCCGACGCCATCGCTGGCTGCGATCGTG
ATCAACCACTACCAGATGAAGGACTCCGTACAGAGCTACTCACTTGGCGGGATGGGTTGCTCAGCGGGACT
CATCTCAATCCACCTCGCAAAGGACCTGCTGCAAGTCTACCCGCGCAAGCGCGCTCGTCTATCTCGACGG
AGAACATCACGCAAAATTTTACCAGGGCAACGAAAAGTCGATGCTCATCTCGAACACGCTCTTCCGAATG
GGCGGCGCCCGCTCCTCCTCTCCGGCCGCCACGCCGACCGGCGCGTCGCCAAGTATCAACTGCTGCACAC
CGTCCGCACGACAAGGGCGCGGACCCGGACGCGTACCGGTGCGTCTTCCAGGAGGAGGACAAGGCGGGGC
ACGTGGGCGTGCGCCTGTGAAAGACGTGATGGAGTGCGCCGCGCGCGATGAAGACCAACATCTCCGTC
CTCGCGCCTCTGATTCTGCCCCGTTTCTGAGCAGGTCCGATTTCTCGCAAACTACGTTGCGCGCAAGTGGCT
GCGAATGAAAGGCGTGAAGGGATACGTGCCGGACTTCACAACGGCCGTGCAGCACTTTTGATCCACACGG
GCGGGCGCGCGGTGCTCGACGCGCTGCAGGCGAACTGTCTGCTCTCAGATTACTACCTCGAGCCGAGCCGT
TACTCCCTGTGGCGCTGGGGTAACGTCTCAAGCGCCTCAGTCTGGTACGAGCTCGACTGGCTCGAAAAGTC
CGGCCGCATCCGGCGGGGCGACAAGGTGTGGCAGATTGGGTTTGGCAGCGGCTTCAAGTGCAACTCGGCCG
TCTGGCGGGCGTGCCGAGCGATGCCCTAGCTACGCCGGCGCGCTCCGCATTGCCAGTGGTTTCGTGACAGAC
AGTCACACTGACGAGTGCGGAGTGACGCTTGACGCTTCCCCCCCCCGCCACCACCTCCACCTCCACCTC
CTTCACTCTCACTCAATCGCGCGGCGGCCAGAGCAGGAGCGCGTCTGTGCTCGCCATCACCGCCTTGTAGT
CCTCGCGCCGCTCGAGCGAGCGCGCTCCATGAGCGGCACGGACGCGAAGCGGAAGAAGACCAATCACA
GCAGAAAAAAAAAAAAAAAAAACTCGAGACTAGTTCTCTCTACCGCGCTGCCGAGCTCAAGCACGGCCGC
GTGTGCATGCTCGCCGTACCCGGCATGCTTGTCCAGGAGGTGTACTCGTGGCCGGCACCCGACGGCGTCTT
CAAGGCGCCGACGCCGCTCGGCGCGCTCTCGACCGTGCCGGCGCTCGGCCCTCATCCAGCTCATCGTCTTCC
TCGGCATCATCGAGGTGCGCTCGGCGAACTACCAGGGCGCGTGCCCGGCGACCTTGGCTTTGACCCGCTC
GG

Figure 8b

MAAPTSPYGA ESPRAAYYP ERANVKMSEA LRVLDEGVHP LVIHSSQILA AALLVTAAVN
HFPKITVADL AEIWRSLQID VAYAFALTAV AVLLLGYYAL RHPRPVYLV D FATWQLRDDK
DDGSLSATSD FFRSTITDCG NFCDESVDFQ MKLFERNQIS ERCYFPPGIR AYRKGERDFD
FSMAAARKEF ETVVFTTVDE LLAKTGVKPR DIDILVVNCS LFNPTPSLAA IVINHYQMKD
SVQSYSLGGM GCSAGLISIH LAKDLLQVYP RKRALVISTE NITQNFYQGN EKSM LISNTL
FRMGGA AVLL SGRHADRRVA KYQLLHTVRT HKGADPDAYR CVFQEEDKAG HVGVRLSKDV
MECAGAAMKT NISVLAPLIL PVSEQVRFLA NYVARKWLRM KGVKGYVPDF TTAVQHFCIH
TGGRAVLDAL QANLSLSYY LEPSRYSLWR WGNVSSASVW YELDWLEKSG RIRRGDKVWQ
IGFGSGFKCN SAVWRACRAM P

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
25 September 2003 (25.09.2003)

PCT

(10) International Publication Number
WO 2003/078639 A3

- (51) International Patent Classification⁷: C12N 15/82, 9/02 (74) Agent: HARRISON GODDARD FOOTE; 31 St. Saviourgate, York YO1 8NQ (GB).
- (21) International Application Number: PCT/GB2003/001099 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (22) International Filing Date: 17 March 2003 (17.03.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
0206308.9 16 March 2002 (16.03.2002) GB
0212133.3 25 May 2002 (25.05.2002) GB
0216013.3 11 July 2002 (11.07.2002) GB
0225489.4 1 November 2002 (01.11.2002) GB
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): THE UNIVERSITY OF YORK [GB/GB]; Heslington, York YO1 5DD (GB).
- Published:
— with international search report
- (72) Inventors; and
- (75) Inventors/Applicants (*for US only*): GRAHAM, Ian, Alexander [GB/GB]; Department of Biology, The University of York, P.O. Box 373, York YO10 5YW (GB). TONON, Thlerry [FR/GB]; Department of Biology, The University of York, P.O. Box 373, York YO10 5YW (GB).
- (88) Date of publication of the international search report: 12 February 2004
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*



WO 2003/078639 A3

(54) Title: TRANSGENIC PLANTS EXPRESSING ENZYMES INVOLVED IN FATTY ACID BIOSYNTHESIS

(57) Abstract: The invention relates to nucleic acid molecules which comprise nucleic acid sequences which encode enzymes involved in the biosynthesis of n-3 fatty acids, particularly docosahexanoic acid (DHA), or variants thereof; polypeptides encoded by said nucleic acids; cells transfected with said nucleic acid sequences and products comprising said nucleic acid sequences, polypeptides and/or cells.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/GB 03/01099

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12N15/82 C12N9/02

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the International search (name of data base and, where practical, search terms used)
EPO-Internal, Sequence Search, WPI Data, PAJ, EMBASE, BIOSIS

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 01 59128 A (ZAEHRINGER ULRICH ; BASF AG (DE); HEINZ ERNST (DE); LERCHL JENS (DE)) 16 August 2001 (2001-08-16) See SEQ ID NO:7 the whole document	1,3-6, 9-14, 16-35
A	WO 00 55330 A (UNIV BRISTOL ; NAPIER JOHNATHAN A (GB)) 21 September 2000 (2000-09-21) the whole document	1-35

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- *A* document defining the general state of the art which is not considered to be of particular relevance
- *E* earlier document but published on or after the international filing date
- *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- *O* document referring to an oral disclosure, use, exhibition or other means
- *P* document published prior to the international filing date but later than the priority date claimed

- *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- *&* document member of the same patent family

Date of the actual completion of the international search

1 September 2003

Date of mailing of the international search report

13.11.03

Name and mailing address of the ISA

European Patent Office, P.O. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Sprinks, M.

INTERNATIONAL SEARCH REPORT

Intern al application No.
PCT/GB 03/01099

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

see PCT/ISA/210 annex

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-35 partially

Nucleic acids encoding a putative elongase (Figure 2a) and subject-matter relating thereto.

2. claims: 1-35 partially

Nucleic acids encoding a putative desaturase (Figures 3a and 3d) and subject-matter relating thereto.

3. claims: 1-35 partially

Nucleic acids encoding a putative desaturase (Figure 4a) and subject-matter relating thereto.

4. claims: 1-35 partially

Nucleic acids encoding a putative acyl-CoA synthase (Figure 6a) and subject-matter relating thereto.

5. claims: 1-35 partially

Nucleic acids encoding a putative diacylglycerol acyltransferase 2 (Figure 7a) and subject-matter relating thereto.

6. claims: 1-35 partially

Nucleic acids encoding a putative elongase 3-ketoacyl-CoA synthase (Figure 8a) and subject-matter relating thereto.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB 03/01099

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 0159128 A	16-08-2001	DE 10005973 A1	16-08-2001
		DE 10023893 A1	22-11-2001
		DE 10063387 A1	12-09-2002
		AU 3924401 A	20-08-2001
		BR 0108198 A	25-03-2003
		CA 2399349 A1	16-08-2001
		CN 1398300 T	19-02-2003
		CZ 20022502 A3	16-10-2002
		WO 0159128 A2	16-08-2001
		EP 1254238 A2	06-11-2002
		HU 0300081 A2	28-05-2003
		JP 2003523746 T	12-08-2003
		NO 20023757 A	08-10-2002
WO 0055330 A	21-09-2000	AU 3308500 A	04-10-2000
		CA 2365096 A1	21-09-2000
		EP 1161542 A1	12-12-2001
		WO 0055330 A1	21-09-2000
		JP 2002538826 T	19-11-2002
		NO 20014542 A	18-09-2001

Form PCT/ISA/210 (patent family annex) (July 1992)

THIS PAGE BLANK (USPTO)